Prudential Financial Inc. Sells 8,800 Shares of Assembly Biosciences Inc (NASDAQ:ASMB)

Share on StockTwits

Prudential Financial Inc. lowered its stake in shares of Assembly Biosciences Inc (NASDAQ:ASMB) by 5.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 146,869 shares of the biopharmaceutical company’s stock after selling 8,800 shares during the period. Prudential Financial Inc. owned approximately 0.57% of Assembly Biosciences worth $1,982,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Alps Advisors Inc. bought a new position in shares of Assembly Biosciences during the 2nd quarter valued at about $721,000. Janus Henderson Group PLC lifted its holdings in shares of Assembly Biosciences by 0.4% during the 2nd quarter. Janus Henderson Group PLC now owns 956,634 shares of the biopharmaceutical company’s stock valued at $12,905,000 after purchasing an additional 3,749 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Assembly Biosciences by 8.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 221,058 shares of the biopharmaceutical company’s stock valued at $3,064,000 after purchasing an additional 17,629 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Assembly Biosciences by 3.3% during the 2nd quarter. Jennison Associates LLC now owns 2,555,637 shares of the biopharmaceutical company’s stock valued at $34,476,000 after purchasing an additional 82,558 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its holdings in shares of Assembly Biosciences by 46.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,899 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 5,050 shares in the last quarter. Hedge funds and other institutional investors own 81.94% of the company’s stock.

Several equities analysts have recently weighed in on ASMB shares. ValuEngine upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Tuesday. Chardan Capital reiterated a “hold” rating and set a $30.00 price objective on shares of Assembly Biosciences in a report on Wednesday, August 7th. Finally, William Blair reiterated a “buy” rating on shares of Assembly Biosciences in a report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $32.50.

NASDAQ ASMB traded up $0.30 during trading on Thursday, hitting $15.12. The stock had a trading volume of 8,614 shares, compared to its average volume of 153,169. The company has a market capitalization of $308.54 million, a PE ratio of -3.77 and a beta of 1.44. The company’s 50-day moving average price is $12.13 and its two-hundred day moving average price is $15.13. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.20 and a current ratio of 9.20. Assembly Biosciences Inc has a 12 month low of $10.58 and a 12 month high of $38.42.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.13) by $0.41. The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.90 million. Assembly Biosciences had a negative return on equity of 46.33% and a negative net margin of 622.25%. As a group, equities analysts anticipate that Assembly Biosciences Inc will post -3.72 earnings per share for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

See Also: What is a support level?

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.